These data suggest a role of tocilizumab in modulating sCD163 plasmatic levels and are in line with those of Hashimoto et al., in which a group of COVID-19 patients exhibited a reduction in serum levels of different inflammatory cytokines after tocilizumab administration (32). The gene discussed is CD163; the disease is COVID-19.